Down-titration and discontinuation of infliximab in rheumatoid arthritis patients with stable low disease activity and stable treatment: An observational cohort study

Annals of the Rheumatic Diseases

Volumn 71, Issue 11, 2012, Pages 1849-1854

  Van Der Maas, Aatke ^a   Kievit, Wietske ^b   Van Den Bemt, Bart J F ^c   Van Den Hoogen, Frank H J ^a   Van Riel, Piet L ^b   Den Broeder, Alfons A ^a  

^a SINT MAARTENSKLINIEK   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c Sint Maartenskliniek ^*  (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; DISEASE MODIFYING ANTIRHEUMATIC DRUG; INFLIXIMAB; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; TUMOR NECROSIS FACTOR INHIBITOR;

ABSENTEEISM; ADULT; AMBULATORY CARE; ARTICLE; BURSITIS; CLINICAL PRACTICE; CLINICAL PROTOCOL; COHORT ANALYSIS; COST CONTROL; DISEASE ACTIVITY; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG WITHDRAWAL; FEMALE; HEALTH CARE COST; HUMAN; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PREVALENCE; PRIORITY JOURNAL; QUALITY OF LIFE; RHEUMATOID ARTHRITIS; TREATMENT DURATION;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG MONITORING; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; JOINTS; MALE; MIDDLE AGED; REMISSION INDUCTION; SEVERITY OF ILLNESS INDEX; TIME FACTORS; WITHHOLDING TREATMENT;

EID: 84867398615     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2011-200945     Document Type: Article

References (37)

1. Allaart CF, Goekoop-Ruiterman YP, de Vries-Bouwstra JK, et al. Aiming at low disease activity in rheumatoid arthritis with initial combination therapy or initial monotherapy strategies: the BeSt study. Clin Exp Rheumatol 2006;24:S-77-82.
2. Bakker MF, Jacobs JW, Verstappen SM, et al. Tight control in the treatment of rheumatoid arthritis: efficacy and feasibility. Ann Rheum Dis 2007;66:iii56-iii60. (Pubitemid 350032636)
3. Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Kerstens PJ, et al. DAS-driven therapy versus routine care in patients with recent-onset active rheumatoid arthritis. Ann Rheum Dis 2010;69:65-9.
4. Grigor C, Capell H, Stirling A, et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet 2004;364:263-9. (Pubitemid 38942816)
5. Fransen J, Moens HB, Speyer I, et al. Effectiveness of systematic monitoring of rheumatoid arthritis disease activity in daily practice: a multicentre, cluster randomised controlled trial. Ann Rheum Dis 2005;64:1294-8. (Pubitemid 41206245)
6. Maini R, St Clair EW, Breedveld F, et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 1999;354:1932-9.
7. Pavelka K, Jarosová K, Suchý D, et al. Increasing the infliximab dose in rheumatoid arthritis patients: a randomised, double blind study failed to confirm its efficacy. Ann Rheum Dis 2009;68:1285-9.
8. van Vollenhoven RF, Brannemark S, Klareskog L. Dose escalation of infliximab in clinical practice: improvements seen may be explained by a regression-like effect. Ann Rheum Dis 2004;63:426-30.
9. van Vollenhoven RF. How to dose infliximab in rheumatoid arthritis: new data on a serious issue. Ann Rheum Dis 2009;68:1237-9.
10. den Broeder AA, van der Maas A, van den Bemt BJ. Dose de-escalation strategies and role of therapeutic drug monitoring of biologics in RA. Rheumatology (Oxford) 2010;49:1801-3.
11. Bongartz T, Sutton AJ, Sweeting MJ, et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006;295:2275-85. (Pubitemid 43736578)
12. Keystone EC. Does anti-tumor necrosis factor-α therapy affect risk of serious infection and cancer in patients with rheumatoid arthritis?: a review of longterm data. J Rheumatol 2011;38:1552-62.
13. Lipsky PE, van der Heijde DM, St Clair EW, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 2000;343:1594-602.
14. Listing J, Strangfeld A, Kary S, et al. Infections in patients with rheumatoid arthritis treated with biologic agents. Arthritis Rheum 2005;52:3403-12. (Pubitemid 41612206)
15. St Clair EW, van der Heijde DM, Smolen JS, et al. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum 2004;50:3432-43. (Pubitemid 39488667)
16. Brocq O, Millasseau E, Albert C, et al. Effect of discontinuing TNFalpha antagonist therapy in patients with remission of rheumatoid arthritis. Joint Bone Spine 2009;76:350-5.
17. Den Broeder AA, Creemers MC, van Gestel AM, et al. Dose titration using the Disease Activity Score (DAS28) in rheumatoid arthritis patients treated with anti-TNFalpha. Rheumatology (Oxford) 2002;41:638-42. (Pubitemid 34618881)
18. Klarenbeek NB, van der Kooij SM, Guler-Yuksel M, et al. Discontinuing treatment in patients with rheumatoid arthritis in sustained clinical remission: exploratory analyses from the BeSt study. Ann Rheum Dis 2010 2011;70(2):315-9.
19. Nawata M, Saito K, Nakayamada S, et al. Discontinuation of infliximab in rheumatoid arthritis patients in clinical remission. Mod Rheumatol 2008;18:460-4.
20. Saleem B, Nizam S, Emery P. Can remission be maintained with or without further drug therapy in rheumatoid arthritis? Clin Exp Rheumatol 2006;24:S-33-6.
21. Tanaka Y, Takeuchi T, Mimori T, et al. Discontinuation of infliximab after attaining low disease activity in patients with rheumatoid arthritis: RRR (remission induction by Remicade in RA) study. Ann Rheum Dis 2010;69:1286-91.
22. van den Bemt BJ, den Broeder AA, Snijders GF, et al. Sustained effect after lowering high-dose infliximab in patients with rheumatoid arthritis: a prospective dose titration study. Ann Rheum Dis 2008;67:1697-701.
23. Prevoo ML, van 't Hof MA, Kuper HH, et al. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995;38:44-8.
24. Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum 2005;52:3381-90. (Pubitemid 41612204)
25. EuroQol - a new facility for the measurement of health-related quality of life. The EuroQol Group. Health Policy 1990;16:199-208.
26. Hakkaart-van Roijen L, Tan SS, Bouwmans CAM. Handleiding voor kostenonderzoek. Methoden en standaard kostprijzen voor economische evaluaties in de gezondheidszorg. 2011.
27. Welsing PM, van Gestel AM, Swinkels HL, et al. The relationship between disease activity, joint destruction, and functional capacity over the course of rheumatoid arthritis. Arthritis Rheum 2001;44:2009-17. (Pubitemid 33644042)
28. Jacobsson LT, Turesson C, Gülfe A, et al. Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis. J Rheumatol 2005;32:1213-8. (Pubitemid 40995372)
29. Dixon WG, Watson KD, Lunt M, et al. Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 2007;56:2905-12. (Pubitemid 47502736)
30. Bartelds GM, Krieckaert CL, Nurmohamed MT, et al. Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up. JAMA 2011;305:1460-8.
31. Svenson M, Geborek P, Saxne T, et al. Monitoring patients treated with anti-TNFalpha biopharmaceuticals: assessing serum infliximab and anti-infliximab antibodies. Rheumatology (Oxford) 2007;46:1828-34. (Pubitemid 350168300)
32. Ducourau E, Mulleman D, Paintaud G, et al. Antibodies toward infliximab are associated with low infliximab concentration at treatment initiation and poor infliximab maintenance in rheumatic diseases. Arthritis Res Ther 2011;13:R105.
33. Krieckaert CL, Bartelds GM, Lems WF, et al. The effect of immunomodulators on the immunogenicity of TNF-blocking therapeutic monoclonal antibodies: a review. Arthritis Res Ther 2010;12:217.
34. Bongartz T, Warren FC, Mines D, et al. Etanercept therapy in rheumatoid arthritis and the risk of malignancies: a systematic review and individual patient data metaanalysis of randomised controlled trials. Ann Rheum Dis 2009;68:1177-83.
35. Leombruno JP, Einarson TR, Keystone EC. The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse events. Ann Rheum Dis 2009;68:1136-45.
36. Johnsen AK, Schiff MH, Mease PJ, et al. Comparison of 2 doses of etanercept (50 vs 100 mg) in active rheumatoid arthritis: a randomized double blind study. J Rheumatol 2006;33:659-64.
37. Kobelt G, Lekander I, Lang A, et al. Cost-effectiveness of etanercept treatment in early active rheumatoid arthritis followed by dose adjustment. Int J Technol Assess Health Care 2011;27:193-200.